10-K: AEON Biopharma Navigates Biosimilar Path Amidst Going Concern Doubt

AEON Biopharma, Inc. reports significant losses and going concern doubt in its 2025 annual filing, while advancing its ABP-450 botulinum toxin biosimilar program with positive analytical study results and strategic financing efforts.

Summary

• AEON Biopharma is a biopharmaceutical company focused on developing ABP-450 as a biosimilar to Botox (onabotulinumtoxinA) for therapeutic indications in the United States via the 351(k) pathway.
• The U.S. therapeutic botulinum toxin market is estimated at $3.3 billion in 2025 and is projected to grow at an annual rate of approximately 8%, with Botox historically dominating approximately 92% of the market in 2024.
• The company reported a net loss of $39.2 million for the year ended December 31, 2025, and an accumulated deficit of $470.8 million.
• As of December 31, 2025, cash and cash equivalents were $3.0 million, and management concluded there is substantial doubt about the company's ability to continue as a going concern, with cash expected to fund operations into the third quarter of 2026.
• Initial analytical studies for ABP-450 demonstrated a 100% amino acid sequence identity match with Botox and highly similar potency and enzymatic activity, receiving constructive feedback from the FDA in a January 2026 BPD Type 2a meeting.
• The company successfully raised approximately $18.3 million net from a public offering in January 2025 and $6.0 million gross from a PIPE financing in November 2025 and January 2026.
• Existing convertible notes totaling $15.0 million with Daewoong were exchanged for equity, a new $1.5 million senior secured convertible note, and warrants.
• AEON settled a lawsuit with Odeon Capital Group LLC for $1.0 million cash, 267,455 shares of common stock, and 125,000 warrants, recording a $0.4 million gain on settlement.
• The company received a notice of non-compliance from NYSE American on February 3, 2025, due to not meeting the minimum stockholders' equity requirement, but its plan to regain compliance by August 3, 2026, was approved.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly speculative investment. While there's promising analytical data for the biosimilar program and a unique market strategy, the severe financial distress, going concern doubt, and NYSE delisting risk overshadow these positives, indicating significant operational and financial challenges.

Positives

• Initial analytical studies for ABP-450 demonstrated a 100% amino acid sequence identity match with Botox and highly similar potency and enzymatic activity, providing a strong scientific foundation for biosimilarity.
• Received constructive feedback from the FDA in a BPD Type 2a meeting in January 2026 on its proposed analytical similarity strategy, providing a clear framework for further development.
• ABP-450 is the same botulinum toxin complex already approved for cosmetic use (Jeuveau) in multiple international markets, including the U.S., supported by a globally validated manufacturing platform.
• The strategic focus on therapeutic indications for ABP-450 aims for a unique pricing model that could improve physician reimbursement and allow for economic incentives, potentially providing a competitive advantage.
• The Phase 2 cervical dystonia program for ABP-450 met its primary and key secondary endpoints, providing supportive human clinical data.
• The company has an experienced management team with specific expertise in biopharmaceutical and botulinum toxin development and commercialization.
• Successful capital raises in early 2025 and early 2026, including $18.3 million net from a public offering and $6.0 million gross from a PIPE financing, have provided some liquidity.
• Material weaknesses in internal control over financial reporting identified in prior years have been remediated during 2025.

Negatives

• The company has incurred recurring significant operating losses and reported an accumulated deficit of $470.8 million as of December 31, 2025.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern, with current cash expected to fund operations only into the third quarter of 2026.
• No revenue has been generated from ABP-450 or any future product candidates to date, and none is expected until regulatory approval and commercialization.
• Phase 2 clinical trials for episodic and chronic migraine were discontinued in May 2024 due to not meeting primary endpoints and as part of cash preservation measures.
• The company received a notice of non-compliance from NYSE American on February 3, 2025, for failing to meet the minimum stockholders' equity requirement of $2.0 million.
• The stock price experienced a significant decline from $38.88 as of December 31, 2024, to $1.10 as of December 31, 2025, indicating substantial loss of market value.
• The company faces an ongoing lawsuit from Aegis Capital Corp. alleging failure to honor a right of first refusal related to a private placement financing.
• The biosimilar licensure pathway for a botulinum toxin product is uncertain and untested, posing regulatory risks.
• The Medicare Drug Price Negotiation Program (IRA) includes Botox for IPAY 2028, which could negatively impact the size, attractiveness, and economics of the therapeutic botulinum toxin market and related competitive markets.

Risks

• Uncertainties around the ability to raise additional capital raise substantial doubt about the company's ability to continue as a going concern.
• Future success depends entirely on the successful and timely regulatory approval and commercialization of ABP-450, which is a lengthy, expensive, and uncertain process.
• ABP-450, if approved, may fail to achieve broad market acceptance by physicians, patients, and third-party payors.
• ABP-450 will face significant competition from existing and new market entrants, potentially preventing significant market penetration.
• Failure to attract and retain senior management and key scientific personnel could hinder development and commercialization efforts.
• Reliance on the Daewoong Agreement for exclusive commercialization rights and sole manufacturing of ABP-450, with any termination or production problems having a material adverse effect.
• Third-party claims of intellectual property infringement, misappropriation, or challenges to patent validity/enforceability could prevent or delay development.
• Extensive government regulation and potential legislative or regulatory healthcare reforms (e.g., ACA, IRA, state price controls) could increase costs, restrict approvals, and affect pricing and reimbursement.
• The price of common stock may be volatile, and sales of a substantial number of securities by existing securityholders could cause the price to fall.
• Additional financing may result in restrictions on operations or substantial dilution to stockholders.
• Failure to regain or maintain compliance with NYSE American continued listing requirements could result in delisting.
• Misconduct by employees, independent contractors, or collaborators, including non-compliance with regulatory standards and healthcare laws, could lead to sanctions and reputational harm.
• Potential international operations expose the company to various risks, including differing regulations, political instability, and currency exchange rates.
• Product liability lawsuits could result in substantial liabilities and require limiting commercialization of ABP-450.
• Inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage.
• Business involves the use of hazardous materials, requiring compliance with environmental laws and regulations.
• Ability to use net operating loss carryforwards and certain other tax attributes may be limited due to ownership changes.
• Computer system failures, security breaches, or data losses could disrupt services, compromise sensitive information, and expose the company to liability.
• Reliance on third-party vendors for critical services; any failure could have a material adverse effect on the business.
• Lack of extensive research coverage by equity analysts could adversely affect the stock price and trading volume.
• Operating as a public company involves significant expenses and requires substantial management attention, potentially straining resources.
• Provisions in the certificate of incorporation, bylaws, and Delaware law have anti-takeover effects that could discourage acquisitions.
• Exclusive forum provisions in corporate documents could limit stockholders' ability to litigate disputes in a preferred judicial forum.

Future Outlook

The company expects to continue incurring significant expenses and increasing net operating losses for the foreseeable future, with no revenue anticipated from ABP-450 until regulatory approval and commercialization. It plans to complete the majority of its analytical comparability program in 2026 and request a BPD Type 2b meeting with the FDA in 2026. The company expects to have sufficient cash to fund its operating plan into the third quarter of 2026 and is actively seeking additional capital. Future U.S. federal healthcare reforms, including the Medicare Drug Price Negotiation Program, are expected to increase pricing pressures and could impact the therapeutic botulinum toxin market.

Management Comments

• "We believe this feedback provides a clear framework for the remaining analytical components of its biosimilar development program and plans to complete the majority of its analytical comparability program in 2026."
• "We are currently planning to request a BPD Type 2b meeting in 2026 to discuss the next phase of the development program to support approval of ABP-450 as a biosimilar to Botox across all approved therapeutic indications."
• "We believe ABP-450, if approved, has the potential to change this dynamic and enable, for the first time, broad switching across established patients."
• "We believe this pricing model would be unique to us within the current therapeutic neurotoxin market, and we believe it would allow physicians to provide treatment with ABP-450 at a more competitive or the same net price as the market leader after rebates and discounts."
• "Our management has concluded that uncertainties around our ability to raise additional capital raise substantial doubt about our ability to continue as a going concern."
• "As of the date of this Report, we expect to have sufficient cash to fund our operating plan into the third quarter of 2026, including funds of $4.2 million received from the Second Closing in January 2026."

Industry Context

StockSavvy.ai notes that AEON Biopharma is targeting a significant and growing U.S. therapeutic botulinum toxin market, estimated at $3.3 billion in 2025 with an 8% annual growth rate. This market is highly concentrated, with Botox historically dominating approximately 92% in 2024. AEON's biosimilar strategy aims to disrupt this by offering a clinically substitutable alternative with a unique pricing model, potentially leveraging a therapeutic-only BLA to avoid cosmetic pricing dilution in Average Selling Price (ASP) calculations, which could be a significant competitive advantage against established players like AbbVie (Botox), Ipsen (Dysport), and Merz (Xeomin). The inclusion of Botox in the Medicare Drug Price Negotiation Program for IPAY 2028 introduces a new layer of market uncertainty and potential pricing pressure for all botulinum toxin therapies, which could both challenge and create opportunities for biosimilar entrants like ABP-450.

Comparison to Industry Standards

• ABP-450 is being developed as a biosimilar to Botox (onabotulinumtoxinA), the market leader, which accounted for approximately 92% of the U.S. therapeutic botulinum toxin market in 2024.
• ABP-450 shares a similar 900 kDa molecular weighting with Botox, which is expected to facilitate physician adoption more rapidly and sustainably than competitors like Dysport (400 kDa) and Xeomin (150 kDa) that require different dilution ratios and injection techniques.
• The same botulinum toxin complex as ABP-450 is already approved for cosmetic use (Jeuveau) in the U.S., EU, and Canada, and has demonstrated non-inferiority to Botox in Phase 3 cosmetic studies.
• AEON's proposed therapeutic-only BLA for ABP-450 aims to create a unique pricing model where the Average Selling Price (ASP) is calculated solely on therapeutic sales, potentially offering a more competitive net price compared to Botox, which includes lower cosmetic sales prices in its ASP calculation.
• Competitors such as Dysport (Ipsen Ltd.), Xeomin (Merz Pharmaceuticals, LLC), and Daxxify (Revance Therapeutics, Inc.) currently have more limited approved labels compared to Botox's twelve indications, which AEON aims to address with a full-label biosimilar approach.
• Revance Therapeutics, Inc. is also developing daxibotulinumtoxinA for therapeutic indications and has a collaboration with Viatris Inc. to develop a biosimilar to Botox, indicating increasing competition in the botulinum toxin biosimilar space.

Management Changes

Corporate Governance

Legal Proceedings

• Odeon Capital Group LLC Lawsuit: Filed September 18, 2023, alleging failure to pay a $1.25 million deferred underwriting fee and seeking approximately $1.7 million. Settled on October 31, 2025, for $1.0 million in cash, 267,455 shares of common stock, and 125,000 warrants (exercise price $2.00, three-year term). A gain on settlement of $0.4 million was recorded.
• Aegis Capital Corp. Lawsuit: Filed November 20, 2025, alleging failure to honor a right of first refusal (ROFR) in Aegis's favor during a self-directed private placement (PIPE). Aegis claimed $1.59 million misappropriated and sought punitive damages and attorneys' fees. AEON filed a motion to dismiss in January 2026, with oral argument scheduled for April 2026.
• Medytox Litigation (Past): Medytox, Inc. previously brought cases against Old AEON and Daewoong alleging theft of a botulinum toxin bacterial strain and misappropriation of trade secrets. This was settled on June 21, 2021, with Medytox granting AEON a non-exclusive, royalty-bearing license to its botulinum toxin strain and specific trade secrets in exchange for 26,680,511 shares of Old AEON common stock and single-digit royalties on net sales for 15 years after the first $1.0 million in commercial sales.

Related Party Transactions

• Daewoong Pharmaceutical Co., LTD.: The company has an exclusive license and supply agreement with Daewoong for ABP-450. Daewoong is the sole manufacturer and supplier of ABP-450.
• Daewoong Pharmaceutical Co., LTD.: In March and April 2024, the company issued $15.0 million in senior secured convertible notes to Daewoong.
• Daewoong Pharmaceutical Co., LTD.: On December 15, 2025 (effective January 21, 2026), the company entered an Exchange Agreement with Daewoong, exchanging the $15.0 million in existing convertible notes for 11,918,380 newly issued common stock shares, 11,236,631 pre-funded warrants, a new $1.5 million senior secured convertible note, and warrants to purchase up to 8 million shares of common stock. This transaction resulted in Daewoong becoming a related party.
• Daewoong Pharmaceutical Co., LTD.: The new $1.5 million senior secured convertible note accrues interest at 15.79% annually and has a maturity date of April 12, 2030. It grants Daewoong a first-priority security interest on substantially all of AEON's assets.
• Daewoong Pharmaceutical Co., LTD.: Seongsoo Park, a designee of Daewoong, serves on the company's board of directors and is scheduled for renomination at the 2026 annual meeting.
• Medytox, Inc.: The company has a non-exclusive, royalty-bearing license agreement with Medytox (effective June 21, 2021) for its botulinum toxin strain and specific trade secrets, in exchange for 26,680,511 shares of Old AEON common stock and single-digit royalties on net sales for 15 years after the first $1.0 million in commercial sales.

Stakeholder Impact

• Shareholders: Face significant dilution from past and potential future equity raises, high stock price volatility, and the risk of delisting from NYSE American. There is a substantial risk of capital loss due to the company's going concern doubt, but also potential for long-term value if ABP-450 is successfully commercialized.
• Employees: The company has a small workforce (8 employees as of December 31, 2025). There is potential for growth and increased opportunities if ABP-450 receives regulatory approval, but also job insecurity due to the company's financial challenges and going concern doubt. Stock-based compensation plans are in place to incentivize employees.
• Customers (future physicians and patients): If ABP-450 is approved, it could offer a new, potentially competitively priced botulinum toxin option for therapeutic uses, which might improve access and reimbursement for debilitating medical conditions.
• Suppliers (Daewoong): Daewoong is a critical partner for manufacturing and licensing, holding significant financial interest and influence through convertible notes, warrants, and board representation. Its operational and financial health directly impacts AEON's ability to develop and commercialize ABP-450.
• Creditors: Daewoong holds a senior secured convertible note and a first-priority security interest on substantially all of AEON's assets, giving it a strong position. Other creditors face higher risk due to the company's going concern doubt and limited liquidity.

Next Steps

• Complete the majority of the analytical comparability program in 2026.
• Request a BPD Type 2b meeting with the FDA in 2026 to discuss the next phase of the development program for ABP-450.
• Actively attempt to secure additional capital to fund operations beyond Q3 2026.
• Regain compliance with NYSE American listing standards by August 3, 2026.
• Oral argument for the Aegis lawsuit motion to dismiss is scheduled for April 2026.
• CMS negotiations with participating manufacturers for the Medicare Drug Price Negotiation Program (including Botox) will occur during 2026, with negotiated maximum fair prices effective January 1, 2028.
• The Board will nominate Seongsoo Park, a designee of Daewoong, to serve as a Class III director at the 2026 annual meeting of stockholders.
• The company will assess the modification of cash-settled restricted stock units to stock-settled in the first quarter of 2026.

Key Dates

Recommendation

AEON Biopharma faces severe financial distress, evidenced by recurring substantial losses, an accumulated deficit of $470.8 million, and management's conclusion of substantial doubt about its ability to continue as a going concern, with only a few quarters of cash runway. The NYSE American non-compliance notice and the significant drop in stock price further underscore the precarious financial position. While the analytical data for ABP-450's biosimilar program is positive and the strategic market approach is innovative, the execution risk for a clinical-stage company with limited resources and no revenue is exceptionally high. The ongoing legal challenges and the highly competitive and regulated pharmaceutical market add layers of uncertainty. Given these overwhelming financial and operational risks, a seasoned investor would likely recommend a strong sell, as the probability of significant capital loss far outweighs the speculative upside.

Keywords

Biopharmaceutical, Botulinum Toxin, ABP-450, Biosimilar, Botox, Therapeutic Indications, FDA Approval, 351(k) Pathway, Clinical Trials, Pharmaceutical Development, NYSE American, Daewoong, Capital Raise, Going Concern, Healthcare Regulation, Intellectual Property, Corporate Governance, Neurotoxin